TRAX · First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics Inc Is A Clinical-Stage Biotechnology Company Focused On Delivering Immunology Therapeutics For Autoimmune And Inflammatory Diseases. Its Clinical-Stage Pipeline Includes Rosnilimab, A Selective Pathogenic T Cell Depleter, For Which It Completed A Phase 2b Trial For The Treatment Of Moderate-To-Severe Rheumatoid Arthritis (Ra), Anb033, A Cd122 Antagonist, In A Phase 1b Trial For Celiac Disease (Ced) And Eosinophilic Esophagitis (Eoe), And Anb101, A Bdca2 Modulator, In A Phase 1a Trial. The Company Operates In One Reportable Segment Focused On Research And Development Activities To Deliver Immunology Therapeutics For Autoimmune And Inflammatory Diseases.